tldrdaily.news logo
Tag

Thromboembolic Events

All articles tagged with #thromboembolic events

health2 years ago

"Bivalent COVID Vaccines Linked to Reduced Risk of COVID-Related Cardiovascular Events, Study Shows"

A new study from the CDC found that staying up to date on COVID-19 vaccines can reduce the risk of COVID-related strokes, blood clots, and heart attacks by around 50 percent in people ages 65 and older and those with conditions that make them more vulnerable. The study, published in the CDC's Morbidity and Mortality Weekly Report, analyzed Medicare beneficiaries and concluded that the bivalent booster dose was 47 percent effective at preventing COVID-related thromboembolic events, with effectiveness waning slightly over time. The authors recommend that adults stay up to date with recommended COVID-19 vaccination to prevent COVID-19-related complications, including thromboembolic events.

via Ars Technica|
#cdc-study#covid-19-vaccines#health
health-medicine2 years ago

"Bivalent mRNA COVID-19 Vaccines Reduce Thromboembolic Events in Elderly and End Stage Renal Disease Patients: US Study"

A study conducted among Medicare beneficiaries aged ≥65 years and those with end stage renal disease (ESRD) receiving dialysis found that bivalent mRNA COVID-19 vaccines were 47% effective in preventing thromboembolic events among immunocompetent persons aged ≥65 years and 51% effective among adults aged ≥18 years with ESRD, compared with receipt of the original monovalent vaccines alone. The findings suggest that COVID-19 vaccines provide protection against COVID-19–related thromboembolic events, emphasizing the importance of staying up to date with COVID-19 vaccination to prevent complications.

via CDC|
#bivalent-vaccine#covid-19#health-medicine
health2 years ago

Persistent Post-COVID Conditions Remain Despite Paxlovid Treatment

A retrospective study of over 9,500 veterans found that nirmatrelvir-ritonavir, a treatment for COVID-19, does not reduce the incidence of most post-COVID conditions (PCCs), except for thromboembolic events. The study analyzed 31 different conditions and found no statistically significant reduction in other PCCs. The results contradict a smaller study that reported lower incidence of 10 out of 13 PCCs. The authors suggest that PCCs may not be a significant factor in COVID-19 treatment decisions based on these findings.

via Medscape|
#covid-19#health#nirmatrelvir-ritonavir